Collaborations are vital to the success of our business. To drive our proprietary programs forward, we have established alliances with leading academic, governmental and pharmaceutical/biotechnology companies.
Our Collaboration Partners:
Rivipansel: In early August, Pfizer reported negative results from the Phase 3 RESET trial (NCT02187003) after it failed to meet the primary endpoint of the study. Pfizer intends to evaluate the underlying data, and with the support of GlycoMimetics, intends to share conclusions at a future medical meeting.
In February 2018, we entered into an agreement with the Haemato Oncology Foundation for Adults in the Netherlands (HOVON) to initiate clinical trial startup activities evaluating uproleselan in adults with newly diagnosed AML but who cannot tolerate intensive chemotherapy. The trial will also evaluate patients with myelodysplastic syndrome, or MDS, who have a high risk of leukemia. The HOVON trial will be the first to evaluate uproleselan together with decitabine in this underserved population of AML and MDS patients; these two populations represent a significant potential expansion opportunity for uproleselan. HOVON intends to enroll approximately 140 patients in the clinical trial, including a control arm. Patients will be evaluated after three cycles of therapy; key efficacy endpoints will include remission rate, disease-free survival and overall survival. The trial is expected to occur in five countries across Europe.
We have had a longstanding research collaboration with the University of Washington/Fred Hutchinson Cancer Research Center that provides support for both nonclinical and clinical studies directed at defining pathways of cell adhesion mediated chemoresistance in AML. Through this collaboration, we have identified several biomarkers of chemoresistance that may prove to be particularly useful to guide the clinical development of uproleselan.
In May 2018, we signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Under the terms of the CRADA, we will collaborate with both the NCI and the Alliance for Clinical Trials in Oncology to conduct a randomized, controlled clinical trial testing the addition of uproleselan to a standard Cytarabine/Daunorubicin regimen (7&3) in older adults with previously untreated AML who are eligible for intensive chemotherapy. The primary endpoint will be overall survival, with a planned interim analysis based on event-free survival (EFS) after the first 250 patients have been enrolled in the study. Under the terms of the CRADA, the NCI may fund additional research, including clinical trials of pediatric patients with AML as well as preclinical experiments and clinical trials evaluating alternative chemotherapy regimens. We will supply uproleselan and provide financial support to augment data analysis and monitoring for the Phase 3 program.
We have had a longstanding partnership with Mater Research Institute—The University of Queensland (MRI-UQ) that provides support of their translational research activities aimed at elucidating the role of E-selectin within the bone marrow microenvironment. Through this collaboration, we have shown that E-selectin plays a crucial role within the vascular niche regulating hematopoietic stem cell dormancy, self-renewal and chemoresistance (Nature Medicine, 2012) and that by inhibiting E-selectin with uproleselan, leukemic stem cells can be sensitized to chemotherapy, potentially improving clinical outcomes for patients.
How to Partner with Us:
We will continue to place an important emphasis on partnerships for our future growth strategy. We are actively exploring collaborations that will augment our core expertise in “glycomimetic” product development.
If you are interested in partnering with us, please email: firstname.lastname@example.org